Alissa focuses her practice on worldwide intellectual property protection and strategic counseling for life sciences, biotechnology, and biomedical engineering clients.
I have experience drafting and prosecuting patents across a wide variety of biotechnologies, including microbiology (microbiome, probiotics, antibiotics), pharmaceuticals (small and large molecule therapeutics), immunology (immuno-cell therapy, targeted cancer therapies, vaccines), regenerative medicine, biochemistry, molecular biology, diagnostic tests, and medical devices.
I previously worked as a patent scientist at Washington University’s Office of Technology Management. I received my JD from Washington University in St. Louis, graduating magna cum laude in the top 10% of the class; I was also accepted into the Order of the Coif. I am registered to practice in the US Patent and Trademark Office as a patent agent. I received my PhD from Washington University in St. Louis in Biological and Biomedical Sciences with a concentration in Molecular Microbiology and Microbial Pathogenesis. I graduated summa cum laude from Brigham Young University, in Provo, UT, where I majored in Physiology and Developmental Biology and minored in Microbiology.
As researchers dissect the complexities of the microbiome, the fight over probiotic patent protection continues to intensify. Worldwide patent litigation demonstrates that microbiome IP is a hotly contested field.
Boston Intellectual Property partner Mark FitzGerald and patent specialist Alissa Young, co-leaders of the IPPG Microbiome team, contributed this article discussing recent FDA approvals of microbiome-based therapies and an anticipated increase in patent enforcement litigation that could follow.
Washington University in St. Louis, J.D., magna cum laude
Washington University in St. Louis, Ph.D.
Brigham Young University, B.S., summa cum laude
Subscribe to stay informed of the latest legal news, alerts, and business trends.Subscribe